Drugs / EXS73565
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06980116 | Mar 2025 → Jun 2028 expected | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2 | Exscientia AI Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXS73565 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06980116 ↗ |
| Route | Oral | “EXS73565 oral administration” NCT06980116 ↗ |